Brokerage firm Leerink Swann Downgrades its rating on Arbutus Biopharma Corp(NASDAQ:ABUS). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by Leerink Swann was issued on Aug 5, 2016.
In a different note, On Jul 8, 2016, Chardan Capital said it Downgrades its rating on Arbutus Biopharma Corp. The shares have been rated ‘Sell’ by the firm. On Jun 16, 2016, Chardan Capital said it Upgrades its rating on Arbutus Biopharma Corp. In the research note, the firm Maintains the price-target to $3.25 per share. The shares have been rated ‘Neutral’ by the firm. Chardan Capital said it Initiates Coverage on Arbutus Biopharma Corp, according to a research note issued on May 16, 2016. The shares have been rated ‘Sell’ by the firm.
Arbutus Biopharma Corp(ABUS) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $300.00K. Analysts had an estimated revenue of $1.52M. Earnings per share were $-0.35. Analysts had estimated an EPS of $-0.41.
Several Insider Transactions has been reported to the SEC. On Aug 26, 2015, Richard C Jr Henriques (director) purchased 1,000 shares at $6.95 per share price.
Arbutus Biopharma Corp formerly Tekmira Pharmaceuticals Corporation is a Canada-based biopharmaceutical company focused on discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the liver caused by hepatitis B virus (HBV). The Company seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells stimulating and reactivating the bodys immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA or cccDNA that is the source of HBV persistence.